COMPANY

Xyone Therapeutics

Location: Weston, MA · source · Oct 28, 2021

Profile checked Oct 10, 2026

Keywords: Relapsed and/or Refractory Solid Tumors MUC1-expressing Advanced Non-Small Cell Lung Cancer Ovarian Cancer GEJ Adenocarcinoma Colorectal Cancer Pancreatic Adenocarcinoma Gastric Cancer XYA02

1Trials (company is sponsor)

Funding and NIH signals

NIH award NIH awarded $396K (SBIR Phase I 1R43AG099628-01, new, notice Sep 17, 2026). NIH RePORTER 1R43AG099628-01 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R43AG099628-01
  Organization: XYONE THERAPEUTICS INC.; City/State: WESTON, MA; Project number: 1R43AG099628-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 396322; Administering IC: National Institute on Aging; Project title: Development and Performance Evaluation of a TruE2 Diagnostic Algorithm for Free Estradiol; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 17, 2026 Trial start Phase 1/Phase 2: Evaluation of XYA02 in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

Sep 15, 2029 (ESTIMATED) · Phase 1/Phase 2 · Evaluation of XYA02 in Patients With Advanced Solid Tumors · NCT07670312

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07670312	Evaluation of XYA02 in Patients With Advanced Solid Tumors	Phase 1/Phase 2	Recruiting	Sep 17, 2026	Sep 15, 2029 (estimated)